0,1,2,3,4,5,6,7,8
,,,Table 4. Cont.,,,,,
,,Target,,Affinity,Inhibition,Virus,,
Target,Library,,Phagotopes,,,,Additional,Reference
,,presentation,,(KD),(IC50),isolates/clades,,
,,,,,,,Inhibition of strand,
Int,7-mer RPL,Recombinant Int,FHNHGKQ,NA,NA,NA,,[105]
,,,,,,,transfer activity,
,,(1) Tat AA,,(1) 10–1000,,,(2) inhibition of,
,(1) HIV-1-infected patient,,,,,,,
(1) Tat,,22–33,(1) 3 Fabs,nM,,,Tat-mediated,[106]
,Fab,,,,,,,
(2) Cyclin T1,,(2) cyclin box,(2) 3R6-1,(2) 107 nM,NA,NA,transactivation and,[107]
,(2) naïve human ScFv,,,,,,,
(3) TAR RNA,,"domain, TRM",(3) 57-mers,(3) 420–550,,,HIV-1 replication,[108]
,(3) 12-mer RPL,,,,,,,
,,(3) TAR RNA,,nM,,,when transfected,
,,,(1) PPx(D/E)R motif,,,,,
,,(1) NCp7 AA 30–,,,,,(2) reduction of virus,
(1) NCp7,(1) 9-mer-c RPL,,"(2) HWWPWW motif,",,,,,[109]
,,52,,NA,NA,NA,release by infected,
(2) Psi RNA,(2) RPLs,,SYQWWWHSPQTL,,,,,[110–112]
,,(2) psi RNA,,,,,cells,
,,,motif,,,,,
,,(1) recombinant,,,,,,
,"(1) mouse ScFv, immunized","Nef, Nef CTL","(1) SdAb19, ScFV3,",,,,,
(1) Nef,,,,,,,(2) inhibition of HIV-,[113–115]
,"llamas VHH, human ScFv",138-10/A24,ScFv27,(1) 2nM,NA,NA,,
(2) Vif,,,,,,,1 replication,"[116,117]"
,(2) 12-mer RPL,(2) recombinant,(2) PxP motif,,,,,
,,Vif,,,,,,
,(1) mouse Fab,,"(1) 5F, 5G",,,,Inhibition of RDDP,"[118,119]"
RT,,Recombinant RT,,NA,NA,NA,,
,(2) human ScFv,,"(2) F-6, 6E9, 5B11",,,,and/or DDDP activity,[120]
,(1) HIV-1-infected patient,,,,,,,
,Fab,,,,,,,
,,,(1) 2 Fabs,,,,,
,(2) 15-mer RPL,,,,,,,
,,,"(2) p1, p3, p19",,,,,
Rev,(3) immunized,Rev,,NA,NA,NA,NA,"[106,121–124]"
,,,(3) Nb190,,,,,
,llamas VHH,,,,,,,
,,,(4) SJS-R1,,,,,
,(4) chimeric rabbit/human,,,,,,,
,Fab,,,,,,,
,,CA protein,,,,,In vitro inhibition of,
Gag,12-mer RPL,,CAI,NA,NA,NA,,[125]
,,(AA 162–190),,,,,capsid assembly,
